08:06 AM EDT, 09/17/2024 (MT Newswires) -- Boston Scientific ( BSX ) said Tuesday that it has received US Food and Drug Administration approval to expand the indication for Ingevity with pacing leads.

Pacing leads are thin wires placed inside the heart and connected to an implantable device for the treatment of symptomatic bradycardia.

This technique could decrease the long-term risk of heart failure associated with traditional right ventricular pacing, the company said.

The expanded indication is based on clinical evidence submitted to the FDA of 400 patients from the INSIGHT-LBBA study.

Price: 83.50, Change: -0.01, Percent Change: -0.01